
Expectations are great for the HexaBody platform, designed to increase the effect of antibody treatments. Current blockbusters, and even abandoned candidate drugs, could turn out to be a future goldmine for the Danish developer of the technology, Genmab.
“In the future we will see a society that is only willing to pay for the very best products, and that’s why our HexaBody platform is so important. You see candidate drugs failing more or less on a daily basis, and it has been like that for a long time,” Genmab CEO, Jan van de Winkel, tells Medwatch. He elaborates:
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app